Academic Journals Database
Disseminating quality controlled scientific knowledge

Dexamethasone - Cyclophosphamide pulse (DCP) therapy in Pemphigus

ADD TO MY LIST
 
Author(s): Roy Renu | Kalla G

Journal: Indian Journal of Dermatology, Venereology and Leprology
ISSN 0378-6323

Volume: 63;
Issue: 6;
Start page: 354;
Date: 1997;
Original page

Keywords: Pemphigus | Dexamethasone | Cyclophosphamide

ABSTRACT
Of the 37 patients enrolled for this treatment, 13 have been lost to follow up and 4 have died. Of the remaining 20, 8 are already in remission (40%), while 12 are still having active disease. Of the 8 patients who are now in remission, 1 is in phase II and taking monthly dexamethasone cyclophosphamide pulse and 50 mg cyclophosphamide daily while in 3 patients all the treatment has already been withdrawn (phase IV). All these patients are being followed up for any recurrence. The duration of remission has been more than 6 months in 7 patients (maximum 2 years). The chief side-effect observed was increased susceptibility to pyogenic and candidal infections of the skin and oral mucosa respectively. The other side-effects noted were generalized weakness and lethargy following DCP (1), irregular menstrual periods (1), amenorrhoea (1), general darkening of complexion (1), steroid psychosis (1), transient eosinophilia (1) and marked transient oligospermia.
Why do you need a reservation system?      Affiliate Program